XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows used in operating activities:    
Net loss $ (13,399) $ (8,241)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 395 366
Amortization of deferred financing costs and debt discount 546 584
In process research and development acquired 250 781
Change in fair value of liability instruments (6) (2,400)
Loss on disposal of property and equipment 66 0
Share-based compensation expense 606 247
Inventory write off 0 107
Non-cash lease expense 24 3
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Accounts receivable 0 1,169
Other current assets (496) 126
Other assets 0 58
Accounts payable and accrued expenses 1,734 (1,234)
Other long-term liabilities 0 0
Net cash used in operating activities (10,280) (8,434)
Cash flows from (used in) investing activities:    
Purchases of property and equipment and intangible assets (144) (93)
Proceeds from sale of property and equipment 62 0
In process research and development acquired from NanoTx Therapeutics 0 (400)
Net cash used in investing activities (82) (493)
Cash flows from financing activities:    
Principal payments of long-term obligations (268) (5,307)
Payment of financing lease liability (8) (117)
Proceeds from exercise of warrants 2,017 1,098
Proceeds from sale of common stock 18,675 4,007
Net cash provided by (used in) financing activities 20,416 (319)
Net increase (decrease) in cash and cash equivalents 10,054 (9,246)
Cash and cash equivalents at beginning of period 8,346 17,592
Cash and cash equivalents at end of period 18,400 8,346
Cash paid during period for:    
Interest 388 567
Supplemental schedule of non-cash investing and financing activities:    
Unpaid offering cost 219 125
Issuance costs paid in common stock 0 463
Common stock issued in payment for in process research and development 0 381
Reclassification of warrants liability to equity $ 0 $ 4,504